AstraZeneca PLC
AZN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $54,073 | $45,811 | $44,351 | $37,417 |
| % Growth | 18% | 3.3% | 18.5% | – |
| Cost of Goods Sold | $10,207 | $8,268 | $12,391 | $12,437 |
| Gross Profit | $43,866 | $37,543 | $31,960 | $24,980 |
| % Margin | 81.1% | 82% | 72.1% | 66.8% |
| R&D Expenses | $13,583 | $10,935 | $9,762 | $9,736 |
| G&A Expenses | $19,669 | $17,683 | $17,448 | $15,144 |
| SG&A Expenses | $20,224 | $18,222 | $17,984 | $15,590 |
| Sales & Mktg Exp. | $555 | $539 | $536 | $446 |
| Other Operating Expenses | $56 | $193 | $457 | -$1,402 |
| Operating Expenses | $33,863 | $29,350 | $28,203 | $23,924 |
| Operating Income | $10,003 | $8,193 | $3,757 | $1,056 |
| % Margin | 18.5% | 17.9% | 8.5% | 2.8% |
| Other Income/Exp. Net | -$1,312 | -$1,294 | -$1,256 | -$1,321 |
| Pre-Tax Income | $8,691 | $6,899 | $2,501 | -$265 |
| Tax Expense | $1,650 | $938 | -$792 | -$380 |
| Net Income | $7,035 | $5,955 | $3,288 | $112 |
| % Margin | 13% | 13% | 7.4% | 0.3% |
| EPS | 1.14 | 1.91 | 1.06 | 0.04 |
| % Growth | -40.3% | 80.2% | 2,550% | – |
| EPS Diluted | 1.13 | 1.91 | 1.06 | 0.04 |
| Weighted Avg Shares Out | 3,100 | 3,124 | 3,096 | 2,836 |
| Weighted Avg Shares Out Dil | 3,126 | 3,124 | 3,120 | 2,854 |
| Supplemental Information | – | – | – | – |
| Interest Income | $345 | $301 | $81 | $43 |
| Interest Expense | $1,682 | $1,589 | $1,330 | $1,276 |
| Depreciation & Amortization | $5,065 | $4,934 | $5,254 | $4,102 |
| EBITDA | $15,438 | $13,422 | $9,085 | $5,113 |
| % Margin | 28.6% | 29.3% | 20.5% | 13.7% |